; and (cc) documents in the patient’s clinical record that the written policies and procedures were provided and discussed; and (III) at the time following the disposal of the controlled substances— (aa) documents in the patient’s clinical record the type of controlled substance, dosage, route of administration, and quantity so disposed; and (bb) the time, date, and manner in which that disposal occurred. . (b) Guidance The Attorney General may issue guidance to hospice programs (as defined in paragraph (5) of section 302(g) of the Controlled Substances Act ( 21 U.S.C. 822(g) ), as added by subsection (a)) to assist the programs in satisfying the requirements under such paragraph (5). (c) Rule of construction relating to State and local law Nothing in this section or the amendments made by this section shall be construed to prevent a State or local government from imposing additional controls or restrictions relating to the regulation of the disposal of controlled substances in hospice care or hospice programs. 3223. GAO study and report on hospice safe drug management (a) Study (1) In general The Comptroller General of the United States (in this section referred to as the Comptroller General ) shall conduct a study on the requirements applicable to, and challenges of, hospice programs with regard to the management and disposal of controlled substances in the home of an individual. (2) Contents In conducting the study under paragraph (1), the Comptroller General shall include— (A) an overview of any challenges encountered by selected hospice programs regarding the disposal of controlled substances, such as opioids, in a home setting, including any key changes in policies, procedures, or best practices for the disposal of controlled substances over time